205 related articles for article (PubMed ID: 21538078)
21. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome.
Wang G; Kuppermann M; Kim B; Phillips KA; Ladabaum U
Am J Manag Care; 2012 May; 18(5):e179-85. PubMed ID: 22694112
[TBL] [Abstract][Full Text] [Related]
22. Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore.
Wang VW; Koh PK; Chow WL; Lim JF
Fam Cancer; 2012 Jun; 11(2):279-89. PubMed ID: 22350504
[TBL] [Abstract][Full Text] [Related]
23. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients.
Pistorius S; Kruger S; Hohl R; Plaschke J; Distler W; Saeger HD; Schackert HK
Gynecol Oncol; 2006 Aug; 102(2):189-94. PubMed ID: 16476474
[TBL] [Abstract][Full Text] [Related]
24. Screening and prevention of hereditary gynecologic cancers.
Kehoe SM; Kauff ND
Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
26. Management of genetic syndromes predisposing to gynecologic cancers.
Miesfeldt S; Lamb A; Duarte C
Curr Treat Options Oncol; 2013 Mar; 14(1):34-50. PubMed ID: 23315239
[TBL] [Abstract][Full Text] [Related]
27. Combined molecular and clinical approach for decision making for surgery in HNPCC patients: a report on three cases in two families.
Pistorius SR; Nagel M; Kruger S; Plaschke J; Kruppa C; Wehrmann U; Schackert HK; Saeger HD
Int J Colorectal Dis; 2001 Nov; 16(6):402-7. PubMed ID: 11760904
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of screening strategies for Lynch syndrome.
Barzi A; Sadeghi S; Kattan MW; Meropol NJ
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
[TBL] [Abstract][Full Text] [Related]
29. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective.
Manchanda R; Menon U; Michaelson-Cohen R; Beller U; Jacobs I
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):31-8. PubMed ID: 19125001
[TBL] [Abstract][Full Text] [Related]
30. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma.
Collins V; Meiser B; Gaff C; St John DJ; Halliday J
Cancer; 2005 Jul; 104(2):273-81. PubMed ID: 15948171
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature.
Fedda FA; Euscher ED; Ramalingam P; Malpica A
Int J Gynecol Pathol; 2020 Jul; 39(4):313-320. PubMed ID: 31851061
[TBL] [Abstract][Full Text] [Related]
32. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
Boilesen AE; Bisgaard ML; Bernstein I
Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
[TBL] [Abstract][Full Text] [Related]
33. Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.
Dębniak T; Gromowski T; Scott RJ; Gronwald J; Huzarski T; Byrski T; Kurzawski G; Dymerska D; Górski B; Paszkowska-Szczur K; Cybulski C; Serrano-Fernandez P; Lubiński J
Hered Cancer Clin Pract; 2015; 13(1):3. PubMed ID: 25606063
[TBL] [Abstract][Full Text] [Related]
34. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
35. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Chen LM; Richardson DL;
Gynecol Oncol; 2015 Jan; 136(1):3-7. PubMed ID: 25238946
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study.
Alblas M; Peterse EFP; Du M; Zauber AG; Steyerberg EW; van Leeuwen N; Lansdorp-Vogelaar I
Cancer Med; 2021 Oct; 10(19):6835-6844. PubMed ID: 34510779
[TBL] [Abstract][Full Text] [Related]
37. For Women, Lynch Syndrome Is About More than Colon Cancer.
Parker WM; Hennig K; Burton-Chase AM
Cancer Prev Res (Phila); 2019 Dec; 12(12):831-836. PubMed ID: 31554630
[TBL] [Abstract][Full Text] [Related]
38. Gynecologic screening in hereditary nonpolyposis colorectal cancer.
Rijcken FE; Mourits MJ; Kleibeuker JH; Hollema H; van der Zee AG
Gynecol Oncol; 2003 Oct; 91(1):74-80. PubMed ID: 14529665
[TBL] [Abstract][Full Text] [Related]
39. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.
Sie AS; Mensenkamp AR; Adang EMM; Ligtenberg MJL; Hoogerbrugge N
Ann Oncol; 2014 Oct; 25(10):2001-2007. PubMed ID: 25081898
[TBL] [Abstract][Full Text] [Related]
40. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
